BackgroundThe irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose
pathogenesis is not completely understood. Its high prevalence and the considerable
effects on quality of life make IBS a disease with high social cost. Recent studies
suggest that low grade mucosal immune activation, increased intestinal permeability and
the altered host-microbiota interactions that modulate innate immune response,
contribute to the pathophysiology of IBS. However, the understanding of the precise
molecular pathophysiology remains largely unknown.Methodology and FindingsIn this study our objective was to evaluate the TLR expression as a key player in the
innate immune response, in the colonic mucosa of IBS patients classified into the three
main subtypes (with constipation, with diarrhea or mixed). TLR2 and TLR4 mRNA expression
was assessed by real time RT-PCR while TLRs protein expression in intestinal epithelial
cells was specifically assessed by flow cytometry and immunofluorescence. Mucosal
inflammatory cytokine production was investigated by the multiplex technology. Here we
report that the IBS-Mixed subgroup displayed a significant up-regulation of TLR2 and
TLR4 in the colonic mucosa. Furthermore, these expressions were localized in the
epithelial cells, opening new perspectives for a potential role of epithelial cells in
host-immune interactions in IBS. In addition, the increased TLR expression in IBS-M
patients elicited intracellular signaling pathways resulting in increased expression of
the mucosal proinflammatory cytokines IL-8 and IL1β.ConclusionsOur results provide the first evidence of differential expression of TLR in IBS
patients according to the disease subtype. These results offer further support that
microflora plays a central role in the complex pathophysiology of IBS providing novel
pharmacological targets for this chronic gastrointestinal disorder according to bowel
habits.
In this population-based study, CD and UC incidences increased dramatically in adolescents across a 24-year span, suggesting that one or more strong environmental factors may predispose this population to IBD.
Background: Irritable bowel syndrome is a multifactorial disease. Although faecal calprotectin has been shown to be a reliable marker of intestinal inflammation, its role in irritable bowel syndrome remains debated. Objective: The aims of this prospective study were to select a subgroup of irritable bowel syndrome patients and to characterise those patients with high faecal calprotectin by systematic work-up. Methods: Calprotectin levels were determined by enzyme-linked immunosorbent assay test in consecutive irritable bowel syndrome patients fulfilling Rome III criteria in whom normal colonoscopy and appropriate tests had excluded organic disease. Calprotectin levels were compared in irritable bowel syndrome patients, healthy controls and patients with active and quiescent Crohn's disease. When the calprotectin level was higher than 50 mg/g, the absence of ANCA/ASCA antibodies and a normal small bowel examination were required to confirm irritable bowel syndrome diagnosis. Additional explorations included assessment of irritable bowel syndrome severity, anxiety and depression, impact on quality of life, glucose and fructose breath tests, rectal distension test by barostat and quantitative and qualitative assessment of inflammation on colonic biopsies. Results: Among the 93 irritable bowel syndrome patients (73% women; 66.7% with diarrhoea) recruited, 34 (36.6%) had reproducibly elevated calprotectin. Although they tended to be older than those with normal calprotectin (P ¼ 0.06), there were no other differences between the two groups. When elevated, calprotectin was correlated with age (P ¼ 0.03, r ¼ 0.22). Conclusions: Elevated faecal calprotectin was observed in one third of patients in this series, without any significant association with a specific clinical phenotype (except age) or specific abnormalities.
Extraintestinal manifestations occurred at lower frequency in elderly-onset compared with pediatric-onset patients. In both age populations, presence of EIM at diagnosis independently increased the need for corticosteroid and immunosuppressive treatment.
Background and study aims: History of gastric surgery is found in 10% of patients with gastroparesis, and vagal lesion is often suspected to be the cause of pylorospasm. Recently, pyloric distensibility measurement using the EndoFLIP ® system showed that pylorospasm was present in 30%-50% of gastroparetic patients. Our objective was to assess whether pylorospasm, diagnosed using EndoFLIP ® system was observed in three different types of gastric surgeries: antireflux surgery, sleeve gastrectomy, and esophagectomy.
Patients and Methods:Pyloric distensibility and pressure were measured using the EndoFLIP ® system in 43 patients from two centers (18 antireflux surgery, 16 sleeve gastrectomy, and nine esophagectomy) with dyspeptic symptoms after gastric surgery, and in 21 healthy volunteers. Altered pyloric distensibility was defined as distensibility below 10 mm 2 /mm Hg as previously reported.Results: Compared to healthy volunteers (distensibility: 25.2 ± 2.4 mm 2 /mm Hg; pressure: 9.7 ± 4.4 mm Hg), pyloric distensibility was decreased in 61.1% of patients in the antireflux surgery group (14.5 ± 3.4 mm 2 /mm Hg; P < .01) and 75.0% of patients in the esophagectomy group (10.8 ± 2.1 mm 2 /mm Hg; P < .05), while pyloric pressure was only increased in the antireflux surgery group (18.9 ± 2.2 mm Hg; P < .01). Pyloric distensibility and pressure were similar in healthy volunteers and in sleeve gastrectomy (distensibility: 20.3 ± 3.8 mm 2 /mm Hg; pressure: 15.8 ± 1.6 mm Hg) groups, with decreased pyloric distensibility affecting 18.7% of sleeve gastrectomy patients.
Conclusion:Antireflux surgery and esophagectomy were associated with pylorospasm although pylorospasm was not found in all patients. Sleeve gastrectomy was not associated with altered pyloric distensibility nor altered pyloric pressure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.